Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 2.9 to 1.6.
Financials
Financial year 2025
LA ROCHE PHARMA from La Roche-en-Ardenne, company number BE0811636216, closed financial year 2025 with a result of € 100,057 after tax. For that financial year LA ROCHE PHARMA recorded a gross margin of € 536,756 and equity of € 851,597. Compared with financial year 2024, the result moved from € 72,056 to € 100,057. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.
€ 851,597
▼ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 100,057
▲ 39% vs 2024
Profit after tax over the fiscal year.
€ 481,886
▼ 18% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 126,432 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
1.6
▼ 0.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 144,109
▲ 16% vs 2024
€ 90,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 42,276
▲ € 36,255 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 507,203
▼ 1% vs 2024
€ 79,870 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 149,727
▲ 16% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 68,061
▲ 22% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 495,572 | € 515,272 | € 507,524 | € 536,756 | ▲ 6% |
| Profit after taxes | € 53,873 | € 51,925 | € 72,056 | € 100,057 | ▲ 39% |
| Equity | € 755,691 | € 807,616 | € 877,972 | € 851,597 | ▼ 3% |
| Total debts | € 1,565,936 | € 1,377,263 | € 1,468,930 | € 1,117,897 | ▼ 24% |
| Cash | € 456,763 | € 501,842 | € 586,112 | € 481,886 | ▼ 18% |
| Land & buildings | € 437,406 | € 407,877 | € 637,254 | € 432,136 | ▼ 32% |
| Retained profit | € 655,691 | € 707,616 | € 777,972 | € 751,597 | ▼ 3% |
| Dividend | € 1,600 | € 0 | € 1,700 | € 126,432 | ▲ € 124,732 |
| Bank debt | € 842,524 | € 682,642 | € 514,019 | € 507,203 | ▼ 1% |
| Balance sheet total | € 2,321,627 | € 2,184,878 | € 2,346,902 | € 1,969,493 | ▼ 16% |
| Employees (FTE) | - | 2.9 | 2.3 | 1.6 | ▼ 0.7 |
Key figures of LA ROCHE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to LA ROCHE PHARMA?
What happened at LA ROCHE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 100,057 (▲ 39% vs 2024). filed late Source: NBB ↗
- MARIE-THERESE GIGOT STEPHANIE became a director. NBB
- POL DEFOY JULIEN became a director. NBB
- New establishment in La Roche-en-Ardenne. KBO
- Start of the company according to the CBE. KBO
In short
From € 53,873 profit in 2022 to € 100,057 profit in 2025.
Paid € 279,408 in corporate taxes since 2022.
Best year ever: 2025, with € 100,057 profit.
On average € 335,500 of value added per employee in 2025.
A new publication or filing at LA ROCHE PHARMA? We notify you, reason included.
Follow LA ROCHE PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind LA ROCHE PHARMA are MARIE-THERESE GIGOT STEPHANIE and POL DEFOY JULIEN.
Directors
According to the 2025 annual accounts
MARIE-THERESE GIGOT STEPHANIE
Director
since 2021
POL DEFOY JULIEN
Director
since 2021
Establishments
Establishment units
Physical locations of this company
Place du Marché 6
6980 La Roche-en-Ardenne
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0811.636.216
- VAT number
- BE 0811.636.216
- Registered office
- Place du Marché 6, 6980 La Roche-en-Ardenne
- Names & denominations
- LA ROCHE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 May 2009
- Peppol
- Active · Active since 11 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten van holdings
Holdings